ProShare Advisors
COGT icon

ProShare Advisors’s Cogent Biosciences COGT Stock Holding History

ProShare Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
28,050
+44
+0.2% +$1.54K ﹤0.01% 780
2026
Q1 		$1.08M Sell
28,006
-4,039
-13% -$149K ﹤0.01% 777
2025
Q4 		$1.14M Buy
32,045
+4,842
+18% +$136K ﹤0.01% 791
2025
Q3 		$391K Buy
27,203
+1,182
+5% +$14K ﹤0.01% 1252
2025
Q2 		$187K Buy
26,021
+1,020
+4% +$5.66K ﹤0.01% 1739
2025
Q1 		$150K Sell
25,001
-6,073
-20% -$47.6K ﹤0.01% 1760
2024
Q4 		$242K Buy
31,074
+7,267
+31% +$72.4K ﹤0.01% 1786
2024
Q3 		$257K Buy
23,807
+6,779
+40% +$66K ﹤0.01% 1571
2024
Q2 		$144K Sell
17,028
-5,178
-23% -$39.3K ﹤0.01% 1601
2024
Q1 		$149K Buy
22,206
+2,953
+15% +$18.3K ﹤0.01% 1746
2023
Q4 		$113K Buy
19,253
+3,130
+19% +$24K ﹤0.01% 1761
2023
Q3 		$157K Buy
16,123
+2,565
+19% +$30.4K ﹤0.01% 1538
2023
Q2 		$161K Buy
13,558
+1,179
+10% +$13.5K ﹤0.01% 1594
2023
Q1 		$134K Sell
12,379
-1,639
-12% -$21K ﹤0.01% 1534
2022
Q4 		$162K Buy
14,018
+1,430
+11% +$17.7K ﹤0.01% 1547
2022
Q3 		$188K Buy
+12,588
New +$173K ﹤0.01% 1425
2022
Q2 		– Sell
-11,101
Closed -$83K – 1850
2022
Q1 		$83K Sell
11,101
-2,633
-19% -$18.3K ﹤0.01% 2064
2021
Q4 		$118K Buy
+13,734
New +$119K ﹤0.01% 2170
2019
Q3 		– Sell
-2,708
Closed -$28K – 1663
2019
Q2 		$28K Sell
2,708
-362
-12% -$4.82K ﹤0.01% 1597
2019
Q1 		$54K Buy
3,070
+32
+1% +$547 ﹤0.01% 1611
2018
Q4 		$53K Buy
+3,038
New +$89.9K ﹤0.01% 1521

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ProShare Advisors's COGT Position: Q2 2026 in Review

ProShare Advisors increased its Cogent Biosciences (COGT) stake by 0.16% in Q2 2026, buying an estimated $1.54K and bringing the position to 28,050 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #780.

ProShare Advisors first reported a position in COGT in Q4 2018 and has held it in 21 quarters since. The position peaked at $1.14M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • ProShare Advisors held 28,050 shares of Cogent Biosciences worth $1.09M as of Q2 2026.
  • ProShare Advisors bought 44 Cogent Biosciences shares in Q2 2026, an estimated $1.54K.
  • Cogent Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #780 holding.
  • ProShare Advisors first reported a position in Cogent Biosciences in Q4 2018 and has held it in 21 quarters since.
  • ProShare Advisors's Cogent Biosciences position peaked at $1.14M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.